FDA nod for Novartis's radiotherapy to bode well for other biotechs - Guggenheim

POINT Biopharma Global

24/03/2022 10:36

** U.S. Food and Drug Administration's approval of Novartis
AG's  NOVN.S  prostate cancer therapy represents a key milestone
for radiopharmaceuticals, brokerage Guggenheim says
    ** Novartis's Pluvicto is a precision treatment combining a
targeting compound, or ligand, with a cancer-killing radioactive
particle; the therapy is approved for patients who have already
received other cancer treatments  urn:newsml:reuters.com:*:nL3N2VQ3UN
    ** Guggenheim says the existing clinical validation,
Novartis's ongoing strategic interest should bode well for an
emerging crop of radiopharmaceutical-focused Biotechs like Y-mAb
Therapeutics  YMAB.O , Point Biopharma Global  PNT.O  and Fusion
Pharmaceuticals  FUSN.O       

 (Reporting by Ankur Banerjee)